DJIA 17,220.98 -58.76 -0.34%
NASDAQ 4,524.40 -55.39 -1.21%
S&P 500 1,997.26 -13.14 -0.65%
market minute promo

Synageva BioPharma (NASDAQ: GEVA)

61.72 -3.08 (-4.75%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

GEVA $61.72 -4.75%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $64.27
Previous Close $64.80
Daily Range $61.60 - $64.99
52-Week Range $44.54 - $119.42
Market Cap $2.0B
P/E Ratio -13.67
Dividend (Yield) $0.00 (0.0%)
Volume 85,924
Average Daily Volume 244,216
Current FY EPS -$6.21

Sector

Healthcare

Industry

Drugs

Synageva BioPharma (GEVA) Description

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of a new class of antiviral drug treatments called fusion inhibitors. Website: http://www.synageva.com/

News & Commentary

5 of Last Week's Biggest Losers

These five stocks suffered double-digit percentage declines last week.

Synageva Slips on Wider-than-Expected Q2 Loss - Analyst Blog

Thursday's ETF Movers: BSCF, XBI

Sector Update: Health Care

Sector Update: Health Care Stocks Following Broader Markets Highers; GlycoMimetics Jumps More Than 1

Sector Update: Health Care Stocks Following Broader Markets Highers; GlycoMimetics Jumps More Than 10% After Naming Cancer-Specialist to Board

3 Stocks Crushed by the Market This Week

No pops and sizzles for these stocks. Just drops and fizzles.

Synageva Shares Tumble Amid Positive Phase 3 Data, A Director's 75% Gain & Analyst Concerns

Synageva's Sebelipase Alfa Meets Primary Endpoint in ARISE - Analyst Blog

Synageva BioPharma Reports Phase 3 Study Meets Primary Endpoint And Six Secondary Endpoints Across M

Synageva BioPharma Reports Phase 3 Study Meets Primary Endpoint And Six Secondary Endpoints Across Multiple Disease-Related Abnormalities

GEVA: Insiders Vs. Shorts

See More GEVA News...

GEVA's Top Competitors

GEVA $61.72 (-4.75%)
Current stock: GEVA
AMGN $141.75 (-1.57%)
Current stock: AMGN
GILD $105.52 (-0.42%)
Current stock: GILD
BIIB $327.59 (-0.50%)
Current stock: BIIB